Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- Evaluate the effect of zoledronate on change in bone mineral density (BMD) at the total
lumbar spine and femoral neck.
Secondary Objectives:
- Evaluate the effect of zoledronate on change in BMD at the total hip
- Evaluate risk factors for developing osteoporosis on chemotherapy
- Determine correlative markers for response to zoledronate 4. Evaluate zoledronate effect
on new bone fractures 5. Evaluate the cost-effectiveness of zoledronic acid (with
calcium and vitamin D) versus standard treatment (calcium and vitamin D alone).